The goal of this clinical research study is to find the highest tolerable dose of Torisel
(temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be
given, in combination, to patients with advanced cancer that has spread or is unable to be
surgically removed. The safety of this drug combination will also be studied.